Biotech Izun successfully completed a Phase II trial of its Israeli-developed IZN-6D4 to treat diabetic foot ulcers (DFU) in 82 patients at seven centers in Israel. DFU is responsible for 84% of diabetes-related lower-leg amputations.
Successful trial of foot ulcer treatment
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.